Ferozsons Laboratories Limited

Condensed Interim Unconsolidated Statement of Profit or Loss (Un-audited)

For the half year ended 31 December 2018

		Half year ended		Quarter ended	
		31 December 2018	31 December 2017	**31 December 2018**	31 December 2017
	Note	**Rupees**		**Rupees**	
Sales - net	*9*	**2,341,392,174**	2,215,745,624	**1,297,405,759**	1,313,387,053
Cost of sales	*10*	**(1,342,001,993)**	(1,443,479,655)	**(743,241,168)**	(901,616,657)
Gross profit		**999,390,181**	772,265,969	**554,164,591**	411,770,396
Administrative expenses		**(173,817,019)**	(151,868,393)	**(91,364,837)**	(80,468,359)
Selling and distribution expenses		**(602,549,725)**	(465,949,650)	**(338,485,611)**	(266,290,950)
Other expenses		**(59,369,912)**	(28,194,640)	**(44,214,552)**	(18,014,687)
Other income		**47,677,104**	41,535,521	**31,194,364**	24,592,383
Profit from operations		**211,330,629**	167,788,807	**111,293,955**	71,588,783
Finance costs		**(10,872,594)**	(6,402,928)	**(6,663,600)**	(4,414,705)
Profit before taxation		**200,458,035**	161,385,879	**104,630,355**	67,174,078
Taxation		**(58,888,674)**	(82,146,927)	**(27,678,259)**	(48,641,132)
Profit after taxation		**141,569,361**	79,238,952	**76,952,096**	18,532,946
Earnings per share - basic and diluted		**4.69**	2.62	**2.55**	0.61

The annexed notes from 1 to 15 form an integral part of this condensed interim unconsolidated financial statements.

Ferozsons Laboratories Limited

Condensed Interim Consolidated Statement of Profit or Loss (Un-audited)

For the half year ended 31 December 2018

		Half year ended		Quarter ended	
		31 December 2018	31 December 2017	**31 December 2018**	31 December 2017
	Note	**Rupees**			
Revenue - net	*10*	**2,651,072,537**	2,491,464,753	**1,440,088,963**	1,455,528,717
Cost of sales	*11*	**(1,656,682,332)**	(1,724,620,136)	**(907,020,616)**	(1,066,770,237)
Gross profit		**994,390,205**	766,844,617	**533,068,347**	388,758,480
Administrative expenses		**(195,331,156)**	(173,880,230)	**(102,017,472)**	(92,436,286)
Selling and distribution expenses		**(623,839,785)**	(512,537,495)	**(351,037,408)**	(293,820,203)
Other expenses		**(75,824,718)**	(29,522,099)	**(44,508,026)**	(18,989,544)
Other income		**64,733,444**	39,052,266	**31,512,200**	23,343,136
Profit from operations		**164,127,990**	89,957,059	**67,017,641**	6,855,583
Finance costs		**(11,581,724)**	(6,953,593)	**(7,079,780)**	(4,662,312)
Profit before taxation		**152,546,266**	83,003,466	**59,937,861**	2,193,271
Taxation	*12*	**(53,941,788)**	(65,055,786)	**(33,783,897)**	(45,276,932)
Profit after taxation		**98,604,478**	17,947,680	**26,153,964**	(43,083,661)
Attributable to:					
Owners of the Company		**107,394,690**	31,916,715	**36,411,291**	(30,542,448)
Non-controlling interests		**(8,790,212)**	(13,969,035)	**(10,257,327)**	(12,541,213)
Profit after taxation		**98,604,478**	17,947,680	**26,153,964**	(43,083,661)
Earnings per share - basic and diluted		**3.56**	1.06	**1.21**	(1.01)

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial statements.